These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23979520)

  • 41. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
    Liu L; Shi B; Wang X; Xiang H
    Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
    Ahmed M; Lorence E; Wang J; Jung D; Zhang L; Nomie K; Wang M
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL.
    Hutter G; Zimmermann Y; Rieken M; Hartmann E; Rosenwald A; Hiddemann W; Dreyling M
    Leukemia; 2012 Nov; 26(11):2442-4. PubMed ID: 22552006
    [No Abstract]   [Full Text] [Related]  

  • 45. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Papin A; Tessoulin B; Bellanger C; Moreau A; Le Bris Y; Maisonneuve H; Moreau P; Touzeau C; Amiot M; Pellat-Deceunynck C; Le Gouill S; Chiron D
    Leukemia; 2019 Oct; 33(10):2442-2453. PubMed ID: 30940906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A breakthrough in mantle cell lymphoma.
    Johns Hopkins Med Lett Health After 50; 2014 Feb; 25(15):8. PubMed ID: 25122938
    [No Abstract]   [Full Text] [Related]  

  • 48. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
    Wiestner A
    J Clin Oncol; 2013 Jan; 31(1):128-30. PubMed ID: 23045586
    [No Abstract]   [Full Text] [Related]  

  • 51. Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
    Sun Y; Ding N; Song Y; Yang Z; Liu W; Zhu J; Rao Y
    Leukemia; 2019 Aug; 33(8):2105-2110. PubMed ID: 30858551
    [No Abstract]   [Full Text] [Related]  

  • 52. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
    Bogner C; Peschel C; Decker T
    Leuk Lymphoma; 2006 Feb; 47(2):195-205. PubMed ID: 16321849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
    Mera WA; Alzihlif M; Taha MO; Khanfar MA
    Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteasome Inhibitor Drugs.
    Fricker LD
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances and future perspectives of noncompetitive proteasome inhibitors.
    Zeng G; Yu Q; Zhuang R; Zhu H; Shao J; Xi J; Zhang J
    Bioorg Chem; 2023 Jun; 135():106507. PubMed ID: 37030106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent advances in irreversible kinase inhibitors.
    Gilbert AM
    Pharm Pat Anal; 2014 Jul; 3(4):375-86. PubMed ID: 25291312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.